Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
#3PRI RANKED
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026/
Topics
Semaglutide · Heart failure with preserved ejection fraction · Type 2 diabetes · Obesity · GLP-1 receptor agonist · Body mass index · KCCQ Clinical Summary Score · Body weight reduction · 6-minute walk distance · Hierarchical composite endpoint · Win ratio · C-reactive protein · Randomized controlled trial · Placebo-controlled trial · Serious adverse events · Symptom burden · Functional impairment · weight loss · Cardiometabolic disease · Inflammation · Worsening heart failure events · Once-weekly dosing · Secondary endpoints · Obesity-related HFpEF · Clinical trial design · STEP-HFpEF DM trial · Cardiovascular events · Anti-inflammatory effect · Diabetes management · Quality of life
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459